Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited

TEVJF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$45.45B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Teva Pharmaceutical Industries LimitedTeva Pharmaceutical Industries Limited98.9-6%2.82.1

Earnings Call Q3 2026

November 3, 2026 - AI Summary

Strong “pivot to biopharma” momentum + raised 2026 guidance (Q3 results) - Q3 revenue: $4.4B (-2% YoY), driven by innovative growth (+32% YoY) offset by weaker generics (notably low generic REVLIMID). - Profitability improved materially: gross margin 58.7% (+~345 bps YoY); non-GAAP EPS +10% YoY; EBITDA +7% YoY; free cash flow $495M (slightly below prior year but in line with expectation). - 2026 guidance raised: revenue range $16.7B–$17.0B (+$175M midpoint); free cash flow $2.1B–$2.4B (increased); innovative product guidance raised (see below). - Upside driver/rationale investors should note: management attributes margin gains to mix shift to innovative products plus transformation savings.
Key innovative performance and raised product outlooks (core of the investment case) - AUSTEDO: $751M in Q3 (+21% YoY); U.S. $727M (+21%); U.S. TRx +18%; milligram dispense +23%. - Important milestone: AUSTEDO reached $2.5B peak-sales target one year early. - Full-year AUSTEDO guidance increased to $2.55B–$2.65B (from earlier higher—midpoint raised +$75M). - UZEDY (schizophrenia LAI): $85M in Q3 (+96% YoY); TRX and LAT +62% YoY. - Management highlighted commercial execution expanding share; UZEDY nearly doubled risperidone LAI share (5%→10%), capturing ~83% of risperidone LAI. - Full-year UZEDY guidance increased to $290M–$310M (midpoint +$20M); launches WELTRUZA expected in Q1 2027 with no major revenue contribution in Q4 2026. - AJOVY (migraine): $269M in Q3 (+61% YoY); U.S. +89%, ex-U.S. strong with volume + share. - Full-year AJOVY guidance increased to $930M–$960M (midpoint +$85M); management reiterated potential > $1B peak sales longer-term.
Pipeline catalysts: upside opportunities, plus at least one clear negative surprise - WELTRUZA: FDA approval (Q3 highlight). Management positions it as differentiated vs typical LAIs: no loading dose, no oral supplementation, no post-injection monitoring, built on olanzapine efficacy; confidence in combined WELTRUZA + UZEDY peak sales of $1.5B–$2B. - Ecopipam (Tourette syndrome): FDA fast-track; expected regulatory approval Q1 2027. - BXCL501 (acquired from BioXcel; closed acquisition): targeted for acute agitation at home; management expects it could add significant value to neuroscience portfolio (potential new at-home treatment pending approval). Acquisition included $57.5M upfront + up to $67.5M contingent tied to FDA timing and sales milestones. - Negative/Surprising: emrusolmin phase II discontinued after independent data monitoring committee interim futility analysis; no safety concerns, but efficacy futility disappoints.

Exclusive for Stockcircle Pro members

Sign upSign Up
$48.83

Current Fair Value

25.3% upside

Undervalued by 25.3% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$45.45 Billion
Enterprise Value$58.35 Billion
Earnings per Share$1.23
Beta0.93
Outstanding Shares1,166,000,000

Return

Return on Equity6.34%ROE
Return on Assets1.26%
Return on Invested Capital5.09%

Valuation & Multiples

P/E Ratio98.89P/E Ratio
PEG-214.09PEG
Price to Sales2.78Price to Sales
Price to Book Ratio6.5Price to Book Ratio
Enterprise Value to Revenue3.39
Enterprise Value to EBIT46.57
Enterprise Value to Net Income115
Total Debt to Enterprise0.29
Debt to Equity2.13Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 11, 2026
EPS Estimate
$0.69
Consensus analyst estimate
Revenue Estimate
$4.22 B
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Teva- Pharmaceutical Industries Ltd.

33,346 employees
CEO: Kaare Schultz

Teva Pharmaceutical Industries Limited operates as a prominent global pharmaceutical firm, involved in the research, development, manufacturing, marketing, and distribution of generic, specialized, and biopharmaceutical products througho...